PREDILIFE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.1 EUR | 0.00% |
|
+5.19% | +24.56% |
| 2023 | Predilife: a project accredited by Finance Innovation | CF |
| 2023 | Predilife S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 289K 314K 427K | Sales 2023 * | - | Capitalization | 26.28M 28.55M 38.87M |
|---|---|---|---|---|---|
| Net income 2022 * | - | Net income 2023 * | - | EV / Sales 2022 | 79.4 x |
| Net cash position 2022 | 3.52M 3.83M 5.21M | Net cash position 2023 * | - 0 0 | EV / Sales 2023 * | - |
| P/E ratio 2022 * |
-
| P/E ratio 2023 * |
-
| Employees | 20 |
| Yield 2022 * |
-
| Yield 2023 * |
-
| Free-Float | 92.59% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 week | +5.19% | ||
| Current month | +37.86% | ||
| 1 month | +64.35% | ||
| 3 months | +48.54% | ||
| 6 months | +19.33% | ||
| Current year | +24.56% |
1 week
6.85
7.30
1 month
4.0824.00
Current year
3.6024.00
1 year
3.6024.00
3 years
3.6024.00
5 years
3.6024.00
10 years
3.6024.00
| Managers | Title | Age | Since |
|---|---|---|---|
Stéphane Ragusa
CEO | Chief Executive Officer | 53 | 03-12-31 |
Émilien Gauthier
CTO | Chief Tech/Sci/R&D Officer | - | 06-12-31 |
Marion Renelier
LAW | General Counsel | - | 15-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Charles Vilgrain
BRD | Director/Board Member | 44 | 17-12-31 |
Stéphane Ragusa
CEO | Chief Executive Officer | 53 | 03-12-31 |
Antoine Bricard
BRD | Director/Board Member | 56 | 17-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 7.1 | 0.00% | 925 |
| 24-05-16 | 7.1 | 0.00% | 1,292 |
| 24-05-15 | 7.1 | +2.90% | 1,087 |
| 24-05-14 | 6.9 | -1.43% | 1,697 |
| 24-05-13 | 7 | -0.71% | 1,457 |
Real-time Euronext Paris, May 17, 2024 at 11:22 am
More quotes
PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women,over 300,000 French women and 500,000 English.
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +24.56% | 28.56M | |
| -31.90% | 9.59B | |
| -6.25% | 3.21B | |
| +25.95% | 2.92B | |
| -13.96% | 2.15B | |
| -16.83% | 1.79B | |
| +72.82% | 1.47B | |
| +29.17% | 770M | |
| -2.62% | 761M | |
| -26.33% | 548M |
- Stock Market
- Equities
- ALPRE Stock